These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 17070440

  • 1. Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy.
    Ando H, Takamura T, Nagai Y, Kaneko S, Kanazawa University Multicenter Diabetes Study Group.
    J Diabetes Complications; 2006; 20(6):367-70. PubMed ID: 17070440
    [Abstract] [Full Text] [Related]

  • 2. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
    Ramirez MA, Borja NL.
    Pharmacotherapy; 2008 May; 28(5):646-55. PubMed ID: 18447661
    [Abstract] [Full Text] [Related]

  • 3. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine.
    Kawai T, Takei I, Tokui M, Funae O, Miyamoto K, Tabata M, Hirata T, Saruta T, Shimada A, Itoh H.
    J Diabetes Complications; 2010 May; 24(6):424-32. PubMed ID: 19716319
    [Abstract] [Full Text] [Related]

  • 4. [Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement].
    Shimada H, Miki T, Kyogoku I, Kawagishi T, Inaba M, Okuno Y, Nishizawa Y, Morii H.
    No To Shinkei; 1998 Sep; 50(9):817-20. PubMed ID: 9789304
    [Abstract] [Full Text] [Related]

  • 5. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.
    Mizuno K, Kato N, Makino M, Suzuki T, Shindo M.
    J Diabetes Complications; 1999 Sep; 13(3):141-50. PubMed ID: 10509874
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic effects of aldose reductase inhibitor on experimental diabetic neuropathy through synthesis/secretion of nerve growth factor.
    Ohi T, Saita K, Furukawa S, Ohta M, Hayashi K, Matsukura S.
    Exp Neurol; 1998 Jun; 151(2):215-20. PubMed ID: 9628756
    [Abstract] [Full Text] [Related]

  • 7. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.
    He J, Gao HX, Yang N, Zhu XD, Sun RB, Xie Y, Zeng CH, Zhang JW, Wang JK, Ding F, Aa JY, Wang GJ.
    Acta Pharmacol Sin; 2019 Jan; 40(1):86-97. PubMed ID: 29930278
    [Abstract] [Full Text] [Related]

  • 8. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
    Hamada Y, Nakamura J, Naruse K, Komori T, Kato K, Kasuya Y, Nagai R, Horiuchi S, Hotta N.
    Diabetes Care; 2000 Oct; 23(10):1539-44. PubMed ID: 11023149
    [Abstract] [Full Text] [Related]

  • 9. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
    Shindo H, Tawata M, Aida K, Onaya T.
    J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
    [Abstract] [Full Text] [Related]

  • 10. Effect of an aldose reductase inhibitor on esophageal dysfunction in diabetic patients.
    Kinekawa F, Kubo F, Matsuda K, Fujita Y, Kobayashi M, Funakoshi F, Uchida N, Watanabe S, Tomita T, Uchida Y, Kuriyama S.
    Hepatogastroenterology; 2005 Feb; 52(62):471-4. PubMed ID: 15816460
    [Abstract] [Full Text] [Related]

  • 11. Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus.
    Steele JW, Faulds D, Goa KL.
    Drugs Aging; 1993 Feb; 3(6):532-55. PubMed ID: 8312678
    [Abstract] [Full Text] [Related]

  • 12. Polyol pathway and protein kinase C activity of rat Schwannoma cells.
    Kamiya H, Nakamura J, Hamada Y, Nakashima E, Naruse K, Kato K, Yasuda Y, Hotta N.
    Diabetes Metab Res Rev; 2003 Feb; 19(2):131-9. PubMed ID: 12673781
    [Abstract] [Full Text] [Related]

  • 13. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study.
    Goto Y, Hotta N, Shigeta Y, Sakamoto N, Kikkawa R.
    Biomed Pharmacother; 1995 Feb; 49(6):269-77. PubMed ID: 7579007
    [Abstract] [Full Text] [Related]

  • 14. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats.
    Yoshida T, Nishioka H, Yoshioka K, Nakano K, Kondo M, Terashima H.
    Diabetes; 1987 Jan; 36(1):6-13. PubMed ID: 3025043
    [Abstract] [Full Text] [Related]

  • 15. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.
    Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M, Toyota T, Nakashima M, Yoshimura I, Sakamoto N, Shigeta Y.
    Diabetes Care; 2006 Jul; 29(7):1538-44. PubMed ID: 16801576
    [Abstract] [Full Text] [Related]

  • 16. Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy.
    Nakayama M, Nakamura J, Hamada Y, Chaya S, Mizubayashi R, Yasuda Y, Kamiya H, Koh N, Hotta N.
    Diabetes Care; 2001 Jun; 24(6):1093-8. PubMed ID: 11375376
    [Abstract] [Full Text] [Related]

  • 17. [Examination of questionnaires regarding diabetic peripheral neuropathy in epalrestat-treated patients and their usefulness in the treatment of the patients during the treatment course].
    Ito A, Ishii-Nozawa R, Ibuki C, Atarashi H, Kataoka H, Takeuchi K.
    Yakugaku Zasshi; 2009 Oct; 129(10):1239-47. PubMed ID: 19797880
    [Abstract] [Full Text] [Related]

  • 18. Effect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus.
    Uchida K, Kigoshi T, Nakano S, Ishii T, Kitazawa M, Morimoto S.
    Clin Ther; 1995 Oct; 17(3):460-6. PubMed ID: 7585850
    [Abstract] [Full Text] [Related]

  • 19. Effects of aldose reductase inhibitor on microneurographically assessed peripheral sympathetic nerve activity in rats.
    Sato D, Kusunoki M, Shinzawa G, Feng Z, Nishina A, Nakamura T.
    Auton Neurosci; 2015 Dec; 193():69-73. PubMed ID: 26272532
    [Abstract] [Full Text] [Related]

  • 20. Sorbitol Is a Severity Biomarker for PMM2-CDG with Therapeutic Implications.
    Ligezka AN, Radenkovic S, Saraswat M, Garapati K, Ranatunga W, Krzysciak W, Yanaihara H, Preston G, Brucker W, McGovern RM, Reid JM, Cassiman D, Muthusamy K, Johnsen C, Mercimek-Andrews S, Larson A, Lam C, Edmondson AC, Ghesquière B, Witters P, Raymond K, Oglesbee D, Pandey A, Perlstein EO, Kozicz T, Morava E.
    Ann Neurol; 2021 Dec; 90(6):887-900. PubMed ID: 34652821
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.